Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 17/20 | 0.61 |
| ▸ | CCNE1 | P24864 | 14/20 | 0.61 |
| ▸ | CCNE2 | O96020 | 13/20 | 0.61 |
| ▸ | CCNA2 | P20248 | 13/20 | 0.61 |
| ▸ | CCNA1 | P78396 | 13/20 | 0.61 |
| ▸ | CDK9 | P50750 | 2/20 | 0.55 |
| ▸ | FLT3 | P36888 | 1/20 | 0.54 |
| ▸ | CDK1 | P06493 | 3/20 | 0.52 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.51 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.51 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20549659 | 1.00 | CDK2 (0.61) | CDK2CCNE1CCNE2CCNA2CCNA1 | |
| SCHEMBL20549658 | 0.84 | CDK5 (0.62) | CDK2CCNE1CCNE2CCNA2CCNA1 | |
| SCHEMBL18313117 | 0.84 | CDK5 (0.62) | CDK2CCNE1CCNE2CCNA2CCNA1 | |
| SCHEMBL22388794 | 0.82 | CDK5 (0.52) | CDK2CCNE1CCNE2CCNA2CCNA1 | |
| SCHEMBL20549618 | 0.82 | CDK5 (0.52) | CDK2CCNE1CCNE2CCNA2CCNA1 | |
| SCHEMBL20549619 | 0.82 | CDK5 (0.52) | CDK2CCNE1CCNE2CCNA2CCNA1 | |
| SCHEMBL21635686 | 0.77 | CDK1 (0.69) | CDK2CCNE1CCNE2CCNA2CCNA1 | |
| SCHEMBL21473890 | 0.77 | CDK1 (0.69) | CDK2CCNE1CCNE2CCNA2CCNA1 | |
| SCHEMBL30822750 | 0.77 | FLT3 (0.57) | CDK2CCNE1CCNE2CCNA2CCNA1 | |
| SCHEMBL6824059 | 0.75 | FLT3 (0.58) | CDK2CCNE1CCNE2CCNA2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE50776-E1 | Inhibitors of cyclin-dependent kinases | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-02-03 | — | — | US | disclosed |
| US-12098154-B2 | Inhibitors of cyclin-dependent kinases | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-09-24 | — | — | US | disclosed |
| US-20230183240-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230183240-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-15 | — | — | US | disclosed |
| EP-3273966-B1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | DANA FARBER CANCER INST INC (US) | 2023-05-03 | — | — | EP | disclosed |
| EP-3273966-B1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | DANA FARBER CANCER INST INC (US) | 2023-05-03 | — | — | EP | disclosed |
| US-20220242865-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-08-04 | — | — | US | disclosed |
| US-11325910-B2 | Inhibitors of cyclin-dependent kinases | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-05-10 | — | — | US | disclosed |
| US-11325910-B2 | Inhibitors of cyclin-dependent kinases | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-05-10 | — | — | US | disclosed |
| CN-107427521-B | Inhibitors of cyclin dependent kinases | 达纳-法伯癌症研究所股份有限公司 | 2021-08-03 | — | — | CN | disclosed |
| US-20200277292-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-09-03 | — | — | US | disclosed |
| US-20200277292-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-09-03 | — | — | US | disclosed |
| US-10550121-B2 | Inhibitors of cyclin-dependent kinases | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-02-04 | — | — | US | disclosed |
| US-10550121-B2 | Inhibitors of cyclin-dependent kinases | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-02-04 | — | — | US | disclosed |
| US-20190315747-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-10-17 | — | — | US | disclosed |
| US-20190315747-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-10-17 | — | — | US | disclosed |
| US-20180319801-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11325910-B2 | Inhibitors of cyclin-dependent kinases | CDK3, CDK13, CDK1 | CDK2 6/4885CCNE1 50/4885CCNE2 47/4885 |
| US-20220242865-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | CDK3, CDK13, CDK1 | CDK2 6/4885CCNE1 50/4885CCNE2 47/4885 |
| US-20200277292-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | CDK3, CDK13, CDK1 | CDK2 6/4885CCNE1 50/4885CCNE2 47/4885 |
| US-10550121-B2 | Inhibitors of cyclin-dependent kinases | CDK3, CDK13, CDK1 | CDK2 6/4885CCNE1 50/4885CCNE2 47/4885 |
| US-20180319801-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | CDK3, CDK13, CDK1 | CDK2 6/4885CCNE1 50/4885CCNE2 47/4885 |
| US-12098154-B2 | Inhibitors of cyclin-dependent kinases | CDK3, CDK13, CDK1 | CDK2 6/4885CCNE1 50/4885CCNE2 47/4885 |
| US-20190315747-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | CDK3, CDK13, CDK1 | CDK2 6/4885CCNE1 50/4885CCNE2 47/4885 |
| US-20230183240-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | CDK3, CDK13, CDK1 | CDK2 6/4885CCNE1 50/4885CCNE2 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.